Lipocine to Present at 27th Annual Oppenheimer Conference
March 14 2017 - 8:00AM
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company,
today announced that Mahesh Patel, President and CEO, and Morgan
Brown, Executive Vice President and CFO, will present a company
overview at the 27th Annual Oppenheimer Healthcare Conference on
Tuesday, March 21, 2017 at 4:30 p.m. ET.
A live audio webcast of the presentation will be available via
the "Investor Relations" page of the Lipocine website,
www.lipocine.com. Please log on through Lipocine's website
approximately 10 minutes prior to the scheduled start time. A
replay of the webcast will also be archived on Lipocine's website
for 90 days following the presentation.
About Lipocine
Lipocine Inc. is a specialty pharmaceutical company developing
innovative pharmaceutical products for use in men's and women's
health using its proprietary drug delivery technologies. Lipocine’s
clinical development pipeline includes three development programs
LPCN 1021, LPCN 1111 and LPCN 1107. LPCN 1021, a novel oral
prodrug of testosterone containing testosterone undecanoate, is
designed to help restore normal testosterone levels in hypogonadal
men. LPCN 1021, was well tolerated and met the primary efficacy
end-point in Phase 3 testing, which utilized 24-hour
pharmacokinetic data for dose adjustments, and is currently being
studied in two additional Phase 3 clinical trials. LPCN 1111,
a novel oral prodrug of testosterone, originated with and is being
developed by Lipocine as a next-generation oral testosterone
product with potential for once-daily dosing and is currently in
Phase 2 testing. LPCN 1107, the potentially first oral
hydroxyprogesterone caproate product candidate indicated for the
prevention of recurrent preterm birth, has been granted orphan drug
designation by the FDA. An End of Phase 2 meeting with the FDA has
been completed. For more information, please visit
www.lipocine.com.
Forward-Looking Statements
This release contains “forward looking statements” that are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and include statements that are not
historical facts regarding Lipocine’s product candidates and
related clinical trials and the FDA review process relating to its
product candidates, plans related to clinical trials, the possible
outcome and timing of such clinical trials, the expected timing of
clinical trial results or any related FDA review process, the path
to approvability by the FDA of Lipocine’s development programs, the
potential uses and benefits of our product candidates, and our
product development efforts. Investors are cautioned that all such
forward-looking statements involve risks and uncertainties,
including, without limitation, the risks that the FDA will not
approve any of our products, risks related to our products,
expected product benefits not being realized, clinical and
regulatory expectations and plans not being realized, advance
regulatory developments and requirements, risks related to the FDA
approval process, the receipt of regulatory approvals, the results
and timing of clinical trials, patient acceptance of Lipocine’s
products, the manufacturing and commercialization of Lipocine’s
products, and other risks detailed in Lipocine’s filings with the
SEC, including, without limitation, its Form 10-K and other reports
on Forms 8-K and 10-Q, all of which can be obtained on the SEC
website at www.sec.gov. Lipocine assumes no obligation to update or
revise publicly any forward-looking statements contained in this
release, except as required by law.
CONTACT:
Morgan Brown
Executive Vice President & Chief Financial Officer
Phone: (801) 994-7383
mb@lipocine.com
Investors:
John Woolford
Phone: (443) 213-0506
john.woolford@westwicke.com
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Apr 2023 to Apr 2024